Skip to content

13F-HR filed by EcoR1 Capital, LLC

EcoR1 Capital, LLC filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 17:04:53 UTC, with 36 holding rows worth $2,252,570,642.

Accession
0000935836-26-000577
Filed
2026-11-16
Accepted by EDGAR
Ingested
Source
EDGAR live feed

Original filing

13F report for Q3 2026

A holdings report, 36 entries on the cover page, a total value of $2,252,570,642 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,252,570,642 with VALUE read as dollars as filed, 13F file number 028-16764. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
ZYMEWORKS INC98985Y108COM22,970,388$608,485,578dollars as filed
ANAPTYSBIO INC032724106COM7,880,094$396,053,524dollars as filed
Bristol-Myers Squibb Company110122108COM3,500,000$218,400,000dollars as filedcall
CG ONCOLOGY INC156944100COMMON STOCK1,871,892$132,698,424dollars as filed
ETON PHARMACEUTICALS INC29772L108COMMON STOCK2,470,920$127,227,671dollars as filed
FIRST TRACKS BIOTHERAPEUTICS337185102ORD SHS *A*3,174,519$112,504,953dollars as filed
AKTIS ONCOLOGY INC01021M104COMMON STOCK4,824,469$93,932,411dollars as filed
CRISPR THERAPEUTICS AG NAMEN AKTH17182108Stock1,389,276$76,854,748dollars as filed
ALTO NEUROSCIENCE INC COM SHS02157Q109Stock2,232,000$56,982,960dollars as filed
LAKEFRONT BIOTHERAPEUTICS NV36315X101SPON ADR1,667,119$49,430,078dollars as filed
ERASCA INC COM29479A108Stock2,950,000$43,247,000dollars as filed
ORIC PHARMACEUTICALS INC68622P109COM3,028,116$40,788,723dollars as filed
NEUROGENE INC64135M105COMMON STOCK1,271,342$35,368,734dollars as filed
ATTOVIA THERAPEUTICS INC04987L102COM2,024,010$34,691,531dollars as filed
FULCRUM THERAPEUTICS INC359616109COMMON STOCK6,803,785$25,174,005dollars as filed
ADARx Pharmaceuticals, Inc.00654F105Common Stock, par value $0.0001 per share1,150,000$22,931,000dollars as filed
STOKE THERAPEUTICS INC86150R107COM835,000$21,710,000dollars as filed
ZENAS BIOPHARMA INC COM98937L105Stock789,500$21,292,815dollars as filed
Electra Therapeutics, Inc.284825106Common Stock, $0.0001 par value per share1,700,000$19,125,000dollars as filed
ATARA BIOTHERAPEUTICS INC046513206COM NEW1,552,000$13,192,000dollars as filed
CAPRICOR THERAPEUTICS INC14070B309COMMON STOCK1,376,580$13,036,213dollars as filed
XENCOR INC98401F105COMMON STOCK500,000$12,475,000dollars as filed
Odyssey Therapeutics, Inc.67613T104COMMON STOCK555,555$12,344,432dollars as filed
AURA BIOSCIENCES INC05153U107COMMON STOCK1,666,667$10,466,669dollars as filed
NURIX THERAPEUTICS INC67080M103COMMON STOCK375,000$8,891,250dollars as filed
Braveheart Bio Inc10567X101COM416,700$8,417,340dollars as filed
PHARVARIS NVN69605108COMMON STOCK235,000$7,454,200dollars as filed
EIKON THERAPEUTICS INC282564103COMMON STOCK855,634$6,879,297dollars as filed
ELOXX PHARMACEUTICALS INC29014R301COM NEW400,000$6,124,000dollars as filed
AARDVARK THERAPEUTICS INC002942100COM720,028$3,794,548dollars as filed
BRIDGEBIO ONCOLOGY THERAPEUT107924102COM NEW889,607$3,647,389dollars as filed
TCGX ACQUISITION CORPG8708J109COM250,000$3,127,500dollars as filed
ZURA BIO LTDG9TY5A101COMMON STOCK679,715$2,827,614dollars as filed
HELIX ACQUISITION CORP IIIG4444S107USD CL A ORD SHS200,000$2,124,000dollars as filed
CONTINEUM THERAPEUTICS INC CL A21217B100Stock64,303$862,946dollars as filed
CG ONCOLOGY INC156944100COMMON STOCK100$7,089dollars as filedcall

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000935836-26-000577this filing2026-11-16